Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
PR Newswire•22/10/2026•10:30 ET
1
Key Highlights
- ➤$5 billion Richmond facility breaks ground for integrated API and finished-medicine production
- ➤Richmond site will produce antibody-drug conjugates and dedicated bioconjugate capacity
- ➤Lilly has announced 10 new U.S. manufacturing sites since 2020
- ➤Facility expected to create 650 high-wage jobs and approximately 1,800 construction jobs
- ➤Lilly commits $40 million to Virginia advanced pharmaceutical manufacturing training network
Expert Statements
David A. Ricks, Chair and CEO of Lilly
“We are developing a new generation of medicines designed to target cancer cells with greater precision, yielding more powerful treatments with potentially fewer side effects. This $5 billion investment means we can make them right here in America. Lilly Richmond will help make sure this innovative science can reach the people who need it.”
Abigail Spanberger, Governor of Virginia
“Lilly's investment is a powerful vote of confidence in Virginia, our people, and our ability to compete for the industries and good jobs that will shape our future. Today's groundbreaking marks an exciting milestone in this partnership, and we are proud that Virginia will play an important, durable role in Lilly's continued global growth and innovation.”
Jonathan Christy, Chairman of the Goochland County Board of Supervisors
“Lilly's groundbreaking marks a significant investment in Goochland County and an exciting step forward for our community. We proudly welcome Lilly and the opportunities this project will create for quality jobs, economic growth, and lifesaving innovation.”
Jamieson Greer, U.S. Trade Representative
“President Trump's America First Trade Policy is accelerating our nation's reindustrialization, incentivizing companies to proudly build, invest, and expand their operations domestically. Lilly's new Richmond facility will ensure that life-saving medicines are manufactured on American soil. Today's groundbreaking stands as a powerful testament that there is no substitute for the resilience of the American economy and the skill of the American worker.”
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020 PR Newswire
First Lilly site to produce both active pharmaceutical ingredients and finished medicines in a fully integrated facility
Get started
Create a free account to read the full story.